Patent · US Active

Bispecific antibodies to ROR1 and CD3

US11306142B2 · kind B2 · utility

3Cited by
2References
16Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJul 5, 2018
Grant dateApr 19, 2022
Priority date—
Expiry dateJul 5, 2038

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/73
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

There is described bispecific antibodies which selectively bind to Receptor Tyrosine Kinase Like Orphan Receptor 1 (ROR1) and the CD3 subunit of the T-Cell Receptor (TCR), their production and their use. Also described is the use of the bispecific antibodies in the treatment of cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.